title: A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.
abstract: Subcutaneous pegylated interferon beta-1a (peginterferon beta-1a [PEG-IFN]) 125 μg every two or four weeks has been studied in relapsing-remitting multiple sclerosis (RRMS) patients in the pivotal Phase 3 ADVANCE trial. In the absence of direct comparative evidence, a network meta-analysis (NMA) was conducted to provide an indirect assessment of the relative efficacy, safety, and tolerability of PEG-IFN versus other injectable RRMS therapies. Systematic searches were conducted in MEDLINE, Embase, and the Cochrane Library, and conference proceedings from relevant annual symposia were hand-searched. Included studies were randomized controlled trials evaluating ≥1 first-line treatments including interferon beta-1a 30, 44, and 22 μg, interferon beta-1b, and glatiramer acetate in patients with RRMS. Studies were included based on a pre-specified protocol and extracted by a team of independent reviewers and information scientists, utilizing criteria from NICE and IQWiG. In line with ADVANCE findings, NMA results support that PEG-IFN every 2 weeks significantly reduced annualized relapse rate, and 3- and 6-month confirmed disability progression (CDP) versus placebo. There was numerical trend favoring PEG-IFN every 2 weeks versus other IFNs assessed for annualized relapse rate, and versus all other injectables for 3- and 6-month CDP (6-month CDP was significantly reduced versus IFN beta-1a 30 μg). The safety and tolerability profile of PEG-IFN beta-1a 125 μg every 2 weeks was consistent with that of other evaluated treatments. Study limitations for the NMA include variant definitions of relapse and other systematic differences across trials, assumptions that populations were sufficiently similar, and inability to perform NMA of adverse events. With similar efficacy compared to other RRMS treatments in terms of annualized relapse rate and 3- and 6-month CDP, a promising safety profile, and up to 93% reduction in number of injections (which may improve adherence), PEG-IFN every 2 weeks offers a valuable alternative treatment option for patients with RRMS.
authors.affiliation: Tolley Health Economics Ltd., Buxton, United Kingdom.
authors.forename: Keith
authors.initials: K
authors.lastname: Tolley
authors.affiliation: St. Vincent's University Hospital, Dublin, Ireland.
authors.forename: Michael
authors.initials: M
authors.lastname: Hutchinson
authors.affiliation: Biogen Idec Inc., Cambridge, MA, United States of America.
authors.forename: Xiaojun
authors.initials: X
authors.lastname: You
authors.affiliation: Biogen Idec Inc., Cambridge, MA, United States of America.
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
authors.affiliation: Biogen Idec Inc., Cambridge, MA, United States of America.
authors.forename: Bjoern
authors.initials: B
authors.lastname: Sperling
authors.affiliation: HERON Commercialization-A Parexel Company, Chandigarh, India.
authors.forename: Ankush
authors.initials: A
authors.lastname: Taneja
authors.affiliation: HERON Commercialization-A Parexel Company, Chandigarh, India.
authors.forename: Mohammed Kashif
authors.initials: MK
authors.lastname: Siddiqui
authors.affiliation: Biogen Idec Inc., Cambridge, MA, United States of America.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Kinter
mesh_terms: D017326:Clinical Trials, Phase III as Topic; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D000068556:Interferon beta-1a / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D000068556:Interferon beta-1a